<DOC>
	<DOC>NCT00442559</DOC>
	<brief_summary>The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.</brief_summary>
	<brief_title>Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Between 2 and 14 years old Diagnosed with asthma, classified as mild persistent asthma according to Global Initiative Asthma Guidelines (GINA) Diagnosed with comorbid allergic rhinitis Patients with suspected sinus infection Prior treatment with high dose inhaled corticosteroid requiring a dose higher than beclomethasone dipropionate 400 ug per day, or equivalent, other medications used in severe cases</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>